Mather Group LLC. Sells 604 Shares of Eli Lilly and Company $LLY

Key Points

• Mather Group LLC. reduced its holdings in Eli Lilly and Company by 7.2%, selling 604 shares during the second quarter, leaving them with 7,770 shares worth approximately $6,057,000.
• Several large investors, including Duquesne Family Office LLC and Cutter Capital Management LP, significantly increased their stakes in Eli Lilly during the first quarter, indicating strong interest among institutional investors.
• Wall Street analysts have mixed ratings on Eli Lilly, with a current average target price of $939.61, while recent reports from JPMorgan and Daiwa showed price objective adjustments to $1,050.00 and $700.00, respectively.

Mather Group LLC. decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,770 shares of the company's stock after selling 604 shares during the period. Mather Group LLC.'s holdings in Eli Lilly and Company were worth $6,057,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Duquesne Family Office LLC boosted its holdings in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after purchasing an additional 32,640 shares during the period. Corient IA LLC bought a new stake in Eli Lilly and Company during the 1st quarter valued at $570,000. LS Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after buying an additional 40 shares during the period. Cutter Capital Management LP bought a new position in shares of Eli Lilly and Company during the 1st quarter worth $14,866,000. Finally, Prism Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the first quarter valued at $207,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LLY. JPMorgan Chase & Co. lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research note on Tuesday, September 16th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a research report on Sunday, August 17th. Berenberg Bank reiterated a "hold" rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Finally, HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their target price for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $939.61.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Down 0.6%

LLY stock opened at $742.51 on Thursday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $939.30. The firm has a 50 day moving average of $736.05 and a 200 day moving average of $768.68. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $702.75 billion, a PE ratio of 48.53, a price-to-earnings-growth ratio of 1.04 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm earned $3.92 EPS. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.